ATYR aTyr Pharma, Inc.
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the Uni…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease aTyr Pharma Inc. (NASDAQ:ATYR) secured a formal agreement with the U.S. Food and Drug Administration (FDA) regarding the Phase 3 study protocol for its lead therapeutic candidate, efzofitimod. Following this regulatory alignment, the company prepares to initiate study-related activities across the U.S. and Europe in the fourth quarter of 2026. Phase 3 Trial Design And Endpoints The upcoming Phase 3 clinical trial aims to assess both the overall safety and effectiveness of efzofitimod in individu | ||
 aTyr Pharma FDA Alignment Sets Protocol for Phase 3 Efzofitimod Study in Pulmonary Sarcoidosis aTyr Pharma plans to begin study-related activities in the fourth quarter of 2026 after reaching FDA alignment on a global Phase 3 efzofitimod trial, although further development will require additional capital. Key Investor TakeawaysaTyr Pharma (NASDAQ:ATYR) has reached alignment with the FDA on the protocol for a Phase 3 efzofitimod study in pulmonary sarcoidosis. | ||
Update: ATyr Pharma Fiscal Q2 Loss Narrows; Announces Restructuring Plans (Updates with restructuring information in the last three paragraphs.) ATyr Pharma (ATYR) reporte | ||
 What It Means To Hold Moderna Stock In A Crash The company's pipeline is more advanced than ever, but its history shows a pattern of deep, prolonged drops when the market turns. | ||